Can I stop taking osimertinib after taking it for 2 and a half years?

A thorough evaluation of the patient's condition is required before discontinuation of medication is considered. Osimertinib is mainly used to treat patients with non-small cell lung cancer who are positive for EGFR gene mutations. These patients usually have received first-line or second-line targeted therapy and have failed or cannot tolerate the treatment. Therefore, before considering stopping the drug, doctors will conduct a detailed assessment of the patient's condition, including the size and location of the tumor, whether there is metastasis, etc. If the patient's condition is stable or improving, discontinuation of medication is more likely.

Doctor's advice is a key factor in deciding whether to stop taking medication. The doctor will comprehensively consider whether the medication needs to be continued or discontinued based on the patient's specific condition, physical condition, and the efficacy and side effects of the drug. Doctors may recommend stopping a medication if they think the patient's condition is under control or if continuing the medication may pose greater risks.

The withdrawal time of osimertinib is relatively safe within a few months, but the specific withdrawal time needs to be determined according to the specific situation of the patient. For patients who have been taking osimertinib for two and a half years, if their condition has remained stable or improved during this period, and no obvious side effects or drug resistance have occurred, they can consider discontinuing the drug under the guidance of a doctor.

There are certain risks associated with discontinuing medication. Some patients may experience rapid deterioration and significant lung cancer progression after stopping the drug. Therefore, before deciding to discontinue medication, patients need to fully communicate with their doctors to understand the possible risks and consequences of discontinuation. At the same time, it is also necessary to closely monitor the patient's condition response after stopping the drug, and regularly evaluate whether continued treatment is needed based on changes in the condition.